BioSpace News Archive

Deals

Fusion Antibodies plc Director/PDMR Shareholding

Fusion Antibodies plc announces that Dr Paul Kerr, Chief Executive Officer of the Company, has purchased 1,290 ordinary shares in the Company at a price of 77 pence per Ordinary Share.

April 29, 2019
·
1 min read
Microbix to Present at Bloom Burton Conference

Healthcare Investor Conference in Toronto on April 30 & May 1

April 29, 2019
·
4 min read
Business

Charles B. Berde, MD, PhD, Joins Scientific Advisory Board of Akelos Inc., Biotechnology Company Developing Opioid Alternatives

Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, adds Dr. Charles Berde to its Scientific Advisory Board.

April 29, 2019
·
4 min read
Drug Development

MorphoSys and I-Mab Biopharma Announce First Patient Dosed in Phase 3 Clinical Study of MOR202/TJ202 in Multiple Myeloma

MorphoSys AG and I-Mab Biopharma announced that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.

April 29, 2019
·
8 min read
Policy

HHS And The American Society Of Nephrology Award Kidneyx Redesign Dialysis Phase 1 Winners

The U.S. Department of Health and Human Services Office of the Chief Technology Officer and the American Society of Nephrology have selected 15 winning teams for Phase 1 of the KidneyX Redesign Dialysis prize competition.

April 29, 2019
·
4 min read